Celonic to manufacture at least 100 million CureVac COVID-19 jabs
pharmafile | March 31, 2021 | News story | Research and Development | COVID-19, COVID-19 vaccine, CureVac, colonic, vaccine production
Celonic are to manufacture more than 100 million doses of CureVac’s COVID-19 vaccine, with 50 million shots expected to be produced before the end of this year.
CureVac expects its broad European manufacturing network to produce up to 300 million doses in 2021, part in thanks to this agreement, which will make use of Celonic’s commercial facility for biologics and ATMPs, in Heidelberg, Germany.
The efficacy of CureVac’s CvnCoV candidate is currently being evaluated in the company’s Phase IIb/III trial in Europe and Latin America.
The company expect data readouts from both these clinical trials by the end of June. Providing this is the case, they will be able to file for formal marketing authorisation in the same timeframe.
CureVac also released preclinical data earlier this month indicating that their vaccine candidate is effective against the B.1.351, or South African, variant of the virus.
The EMA has granted authorisation to four vaccine candidates so far: Pfizer-BioNTech, Johnson & Johnson, Moderna, and Oxford-AstraZeneca.
Dr Florian von der Mülbe, Chief Production Officer of CureVac, said: “Manufacturing of sufficient quantities of vaccine is critical to combating the COVID-19 pandemic. With this partnership, we are further extending our integrated European manufacturing network, reinforcing the overall production capacity for our COVID-19 vaccine candidate, CVnCoV.”
Dr Konstantin Matentzoglu, CEO of Celonic, added: “Since the onset of the pandemic, Celonic has committed extensive breadth of complex bio-solutions development expertise and manufacturing resources to this global challenge. We have invested heavily to support our partners in bringing novel COVID-19 therapeutics and vaccines to patients, at an accelerated pace.
“Celonic is proud to collaborate with CureVac as part of an expansive manufacturing network in this global fight against COVID-19 by contributing to the production of its mRNA-based COVID-19 vaccine candidate, CVnCoV. With a dedicated and highly motivated team in place, Celonic is well positioned to have produced the first 50 million doses before end of 2021.”
Jack Goddard
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
